Matches in SemOpenAlex for { <https://semopenalex.org/work/W71535241> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W71535241 endingPage "54" @default.
- W71535241 startingPage "144" @default.
- W71535241 abstract "Screening for hyperlipidemia is a substantial cost burden, as is its treatment. The choice of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and the dose level may have significant implications for both efficient and cost effective therapy.To compare the efficiency and cost of statins.A meta-analysis was conducted of randomized, controlled trials of monotherapy with fixed doses of statins published in the literature until June 1998. Two authors independently extracted data from 49 trials comprising 14,130 patients. The percentage reduction (95% confidence intervals) of low density lipoprotein (LDL) cholesterol levels was calculated using a random-effects model. Cost efficiency was defined as the percentage decline of LDL cholesterol per dollar of drug cost.The population evaluated had a mean baseline LDL cholesterol concentration of 5.31 mmol/L, a mean age of 53.5 years and a mean 59% proportion of males. In reducing LDL cholesterol concentrations to less than 25% of the baseline concentration, a significantly higher cost efficiency was achieved with simvastatin 2.5 mg (-53.3%/dollar). By targeting a reduction between 25% and 29%, significantly higher cost efficiencies were found with simvastatin 5 mg (-28.9%/dollar), cerivastatin 0.2 mg (-23.8%/dollar) and fluvastatin 40 mg (-23.3%/dollar). For reductions in LDL cholesterol concentrations of 30% to 34%, statistically higher cost efficiencies were achieved with simvastatin 20 mg (-15.0%/dollar) and pravastatin 40 mg (-14. 4%/dollar). Finally, atorvastatin 10 mg yielded a value of -22. 9%/dollar for a 36% reduction in LDL cholesterol concentration.At current prices of the various doses of statins, the cost efficiency of standard and more aggressive therapies varies substantially. In the context of health care budgets, targeting at-risk patients and using statins judiciously should facilitate the efforts of clinicians and patients to reduce lipid profiles optimally and decrease the cost burden." @default.
- W71535241 created "2016-06-24" @default.
- W71535241 creator A5001923311 @default.
- W71535241 creator A5025103237 @default.
- W71535241 creator A5036618091 @default.
- W71535241 date "2000-01-01" @default.
- W71535241 modified "2023-10-03" @default.
- W71535241 title "Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia." @default.
- W71535241 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11044760" @default.
- W71535241 hasPublicationYear "2000" @default.
- W71535241 type Work @default.
- W71535241 sameAs 71535241 @default.
- W71535241 citedByCount "9" @default.
- W71535241 crossrefType "journal-article" @default.
- W71535241 hasAuthorship W71535241A5001923311 @default.
- W71535241 hasAuthorship W71535241A5025103237 @default.
- W71535241 hasAuthorship W71535241A5036618091 @default.
- W71535241 hasConcept C104950815 @default.
- W71535241 hasConcept C126322002 @default.
- W71535241 hasConcept C126894567 @default.
- W71535241 hasConcept C134018914 @default.
- W71535241 hasConcept C134651460 @default.
- W71535241 hasConcept C168563851 @default.
- W71535241 hasConcept C181199279 @default.
- W71535241 hasConcept C185592680 @default.
- W71535241 hasConcept C2776329913 @default.
- W71535241 hasConcept C2776839432 @default.
- W71535241 hasConcept C2777482532 @default.
- W71535241 hasConcept C2778163477 @default.
- W71535241 hasConcept C2778417548 @default.
- W71535241 hasConcept C2779091943 @default.
- W71535241 hasConcept C2779415389 @default.
- W71535241 hasConcept C2779519902 @default.
- W71535241 hasConcept C44249647 @default.
- W71535241 hasConcept C55493867 @default.
- W71535241 hasConcept C555293320 @default.
- W71535241 hasConcept C71924100 @default.
- W71535241 hasConcept C98274493 @default.
- W71535241 hasConceptScore W71535241C104950815 @default.
- W71535241 hasConceptScore W71535241C126322002 @default.
- W71535241 hasConceptScore W71535241C126894567 @default.
- W71535241 hasConceptScore W71535241C134018914 @default.
- W71535241 hasConceptScore W71535241C134651460 @default.
- W71535241 hasConceptScore W71535241C168563851 @default.
- W71535241 hasConceptScore W71535241C181199279 @default.
- W71535241 hasConceptScore W71535241C185592680 @default.
- W71535241 hasConceptScore W71535241C2776329913 @default.
- W71535241 hasConceptScore W71535241C2776839432 @default.
- W71535241 hasConceptScore W71535241C2777482532 @default.
- W71535241 hasConceptScore W71535241C2778163477 @default.
- W71535241 hasConceptScore W71535241C2778417548 @default.
- W71535241 hasConceptScore W71535241C2779091943 @default.
- W71535241 hasConceptScore W71535241C2779415389 @default.
- W71535241 hasConceptScore W71535241C2779519902 @default.
- W71535241 hasConceptScore W71535241C44249647 @default.
- W71535241 hasConceptScore W71535241C55493867 @default.
- W71535241 hasConceptScore W71535241C555293320 @default.
- W71535241 hasConceptScore W71535241C71924100 @default.
- W71535241 hasConceptScore W71535241C98274493 @default.
- W71535241 hasIssue "3" @default.
- W71535241 hasLocation W715352411 @default.
- W71535241 hasOpenAccess W71535241 @default.
- W71535241 hasPrimaryLocation W715352411 @default.
- W71535241 hasRelatedWork W158929996 @default.
- W71535241 hasRelatedWork W1778499707 @default.
- W71535241 hasRelatedWork W2011843648 @default.
- W71535241 hasRelatedWork W2015283800 @default.
- W71535241 hasRelatedWork W2038338711 @default.
- W71535241 hasRelatedWork W2242789166 @default.
- W71535241 hasRelatedWork W2517970972 @default.
- W71535241 hasRelatedWork W285758932 @default.
- W71535241 hasRelatedWork W71535241 @default.
- W71535241 hasRelatedWork W2947959412 @default.
- W71535241 hasVolume "7" @default.
- W71535241 isParatext "false" @default.
- W71535241 isRetracted "false" @default.
- W71535241 magId "71535241" @default.
- W71535241 workType "article" @default.